Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

University of Alberta

$90,000.00

Molecular pharmacology of Kv channel activators: an emerging class of anti-epileptic drugs.

EF 2019-20

Résumé
Epilepsy is a nervous system disorder that causes seizures from abnormal brain activity. It is a disease that affects nearly 1% of the population worldwide. Many old drugs are still used to treat epilepsy eventhough several challenges still persist including drug resistant and adverse side effects. These problems address the need to introduce new anti-epileptic drugs for treatment of this complicated disease. Understanding how these drugs work is of great importance for the development and delivery of safe and effective pharmaceuticals. A common cause of Epilepsy is dysfunction of proteins, known as ion channels, that disrupt electrical signaling in the brain. In particular, dysfunction of ion channels that are selective to potassium ions (potassium channels) have been linked to different forms of epilepsy. Targeting these potassium channels has become a promising endeavour for drug companies and scientists. The drug, Retigabine, became the first FDA approved pharmaceutical option in its class. Retigabine targets potassium channels and works by promoting the open state of these channels and preventing abnormal brain activities that lead to seizures. However, due to health and financial reasons, Retigabine has recently been discontinued as a treatment option for epilepsy. While Retigabine is the most recognized drug in this category, several existing and emerging potassium channel targeting drugs, each with very different mechanisms of action, remain to be investigated or completely understood. My research aims to study in detail this new class of anti-epileptic drug, in connection with the pharmaceutical industry, to improve viable treatment options for epilepsy.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
412739
Name
Lamothe Shawn M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Molecular pharmacology of Kv channel activators: an emerging class of anti-epileptic drugs.
Programtype2
Fellowship Programs
Orgnameinp2
University of Alberta
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Abnormal Brain Activity; Drug Discovery And Development; Epilepsy And Epileptic Seizures; Genetic Mutations; Ion Channels; Neurodevelopmental Delay; Neurons; Novel Subtypes Of Potassium Channel Activators; Potassium Channels; Protein Function
Abstract
Epilepsy is a nervous system disorder that causes seizures from abnormal brain activity. It is a disease that affects nearly 1% of the population worldwide. Many old drugs are still used to treat epilepsy eventhough several challenges still persist including drug resistant and adverse side effects. These problems address the need to introduce new anti-epileptic drugs for treatment of this complicated disease. Understanding how these drugs work is of great importance for the development and delivery of safe and effective pharmaceuticals. A common cause of Epilepsy is dysfunction of proteins, known as ion channels, that disrupt electrical signaling in the brain. In particular, dysfunction of ion channels that are selective to potassium ions (potassium channels) have been linked to different forms of epilepsy. Targeting these potassium channels has become a promising endeavour for drug companies and scientists. The drug, Retigabine, became the first FDA approved pharmaceutical option in its class. Retigabine targets potassium channels and works by promoting the open state of these channels and preventing abnormal brain activities that lead to seizures. However, due to health and financial reasons, Retigabine has recently been discontinued as a treatment option for epilepsy. While Retigabine is the most recognized drug in this category, several existing and emerging potassium channel targeting drugs, each with very different mechanisms of action, remain to be investigated or completely understood. My research aims to study in detail this new class of anti-epileptic drug, in connection with the pharmaceutical industry, to improve viable treatment options for epilepsy.
Competitiondate
201910
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Lamothe, Shawn M
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~